A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
11/2009
11/05/2009	CA2720846A1 Novel inhibitors of hepatitis c virus replication
11/05/2009	CA2720008A1 Porous crystalline hybrid solid for adsorbing and releasing gas of biological interest
11/04/2009	EP2113509A2 Modulation of the expression of STAT-1 dependent genes
11/04/2009	EP2113252A1 A forsythoside injection and preparation thereof
11/04/2009	EP2113251A1 Use of compounds as inhibitors for helicobacter flavodoxin
11/04/2009	EP2113249A1 Antimycotic patch
11/04/2009	EP1615613B1 Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
11/04/2009	EP1467743B1 Pharmaceutical combinations comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical application
11/04/2009	EP1420645B1 Multivesicular emulsion topical delivery systems
11/04/2009	EP1204430B1 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
11/04/2009	EP1098910B1 Antigenic complex comprising immunostimulatory peptide, cd4, and chemokine receptor domain for hiv treatment and immune disorders
11/04/2009	CN101573344A Antifungal triazole derivatives, method for the preparation thereof and pharmaceutical composition containing same
11/04/2009	CN101573342A HIV inhibiting 5,6-substituted pyrimidines
11/04/2009	CN101569612A Lyophilized clindamycin phosphate powder needle reagent
11/03/2009	US7612238 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases
11/03/2009	US7612205 Crystals of quinolinecarboxylic acid derivative solvate
11/03/2009	US7612192 Neisseria genomic sequences and methods of their use
11/03/2009	US7612168 Modified HIV peptides, antigens, compositions, immunoassay kit and a method of detecting antibodies induced by HIV
11/03/2009	US7612115 Citric acid, polyethylene glycol, and ofloxacin; low gelation temperatures; bioavailability
11/03/2009	US7612103 Such as 14-O-[4-hydroxy-N-valyl-piperidin-3-yl]-sulfanylacetylmutilin
11/03/2009	US7612087 Heterocyclic compounds as inhibitors of beta-lactamases
11/03/2009	US7612083 Urea substituted imidazoquinoline ethers
11/03/2009	US7612079 2-(hydroxypiperidin-1-yl or hydroxyisoalkylamino)-6(3-nitrophenylamino, 3,4-dimethoxybenzylamino, pyrid-2-yl-methylamino, pyrid-4-yl-methylamino or indan-5-amino)-9-(isopropyl or cyclopentyl)purines; cell cyclin kinase inhibitors for treating cancer, leukemia, psoriasis and neuronal apoptosis
11/03/2009	US7612059 Pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use
11/03/2009	US7612053 7-Substituted fused ring tetracycline compounds
11/03/2009	US7612037 Vancomycin coupled through an oxime to and aminochlorothiazolo pyridinium substituted bicyclic hetero ring; antibiotics
11/03/2009	US7612036 Such as methyl (2S,5S,8R/S)-8-acetamido-2-allyl-9-[6-allyl-9-tert-butoxycarbonyl-9H-carbazol-3-yl]-3,6-diaza-5-{3-[(2,2,5,7,8-pentamethylchroman-6-sulfonyl)-guanidino]propyl}-4,7-dioxononanoate; for treatment of bacterial infections, such as those caused by vancomycin resistant microorganisms
11/03/2009	US7612033 administering to the cell a composition which comprises the compound to be delivered and an organic halide such as a perfluorocarbon; ultrasound
11/03/2009	US7611729 Dosage forms having prolonged active ingredient release
11/03/2009	US7611721 Adjuvant combination formulations
11/03/2009	US7611720 Tuberculosis vaccines including recombinant BCG strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase
11/03/2009	CA2418008C Antifungal ketoconazole composition for topical use
11/03/2009	CA2383220C Controlled release pellet formulation
11/03/2009	CA2353133C Treatment of disorders secondary to organic impairments
11/03/2009	CA2205379C Yeast-based delivery vehicles
11/03/2009	CA2188293C Herpesviruses transformed to express gd in vitro
10/2009
10/30/2009	CA2629318A1 Clean hands, disinfectant container pad (germ protector)
10/29/2009	WO2009132343A1 Nanoemulsions for treating onchomycosis
10/29/2009	WO2009132342A1 Nanoemulsions for treating fungal, yeast and mold infections
10/29/2009	WO2009132209A2 Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
10/29/2009	WO2009132135A1 1' -substituted carba-nucleoside analogs for antiviral treatment
10/29/2009	WO2009132123A1 Carba-nucleoside analogs for antiviral treatment
10/29/2009	WO2009132101A1 Methods of treating fungal infections
10/29/2009	WO2009131973A1 Quinolone derivatives useful as antibacterial agents
10/29/2009	WO2009131940A1 Limk2 inhibitors, compositions comprising them, and methods of their use
10/29/2009	WO2009131696A1 Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
10/29/2009	WO2009131654A2 Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives
10/29/2009	WO2009131548A1 Multimeric forms of antimicrobial peptides
10/29/2009	WO2009131453A1 Compositions and methods to enhance the immune system.
10/29/2009	WO2009131065A1 Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient
10/29/2009	WO2009130481A1 Pyrrole antifungal agents
10/29/2009	WO2009130256A2 Compositions and methods for preventing or treating aids
10/29/2009	WO2009129627A1 Novel resveratrol compositions
10/29/2009	WO2009129616A1 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
10/29/2009	WO2009129561A1 Anti-viral nutraceutical
10/29/2009	WO2009085025A3 System and method for sparql-query processing using parametrized-sparql-query in dbms-based systems
10/29/2009	WO2009046856A3 Use of serorphin as a therapeutic agent
10/29/2009	WO2009046824A3 Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis
10/29/2009	WO2009043505A3 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
10/29/2009	WO2009043504A3 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer
10/29/2009	WO2009040089A3 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
10/29/2009	WO2009039996A3 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent
10/29/2009	WO2009039977A3 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection
10/29/2009	WO2009037264A3 Colonic delivery of antimicrobial agents
10/29/2009	WO2009033781A3 Use of k237 as therapeutic agent
10/29/2009	WO2009033751A3 Use of leu-enkephalin as a therapeutic agent
10/29/2009	WO2009033718A3 Use of anti -inflammatory peptide 1 as a therapeutic agent
10/29/2009	WO2009021121A4 Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
10/29/2009	US20090270881 Facial blemish removing device
10/29/2009	US20090270591 Novel surface antigen
10/29/2009	US20090270506 Crystalline structure of oxidosqualene synthase
10/29/2009	US20090270499 Process for Synthesizing Atazanavir
10/29/2009	US20090270497 Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
10/29/2009	US20090270496 Antifungal compounds
10/29/2009	US20090270456 Novel chemical compounds
10/29/2009	US20090270441 Macrolides
10/29/2009	US20090270440 Bioavailability of active substances having an amidine function in medicaments
10/29/2009	US20090270436 Spirochromanon derivatives
10/29/2009	US20090270431 Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections
10/29/2009	US20090270429 Antiviral formulation
10/29/2009	US20090270428 Cyclopropanecarboxylate esters of acyclovir
10/29/2009	US20090270427 Purine derivatives
10/29/2009	US20090270423 Antibacterial small molecules and methods for their synthesis
10/29/2009	US20090270379 Quinolone derivatives useful as antibacterial agents
10/29/2009	US20090270375 Spiro antibiotic derivatives
10/29/2009	US20090270374 Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
10/29/2009	US20090270352 Tenofovir Disoproxil Hemi-Fumaric Acid Co-Crystal
10/29/2009	US20090270348 Sulfoalkyl Ether Cyclodextrin Compositions
10/29/2009	US20090269421 Coating material
10/29/2009	US20090269396 Dual action, inhaled formulations providing both an immediate and sustained release profile
10/29/2009	US20090269394 Methods and compositions for treating onchomycosis
10/29/2009	US20090269372 Enhanced Antiviral Activity Against Foot and Mouth Disease
10/29/2009	US20090269368 Pseudomonas exotoxin a-like chimeric immunogens
10/29/2009	US20090269365 Immunogenic vaccinia peptides and methods of using same
10/29/2009	US20090269363 Method for screening peptides for use in immunotherapy
10/29/2009	US20090269362 Method for Controlling Immunodominance
10/29/2009	US20090269361 Constructs for delivery of therapeutic agents to neuronal cells
10/29/2009	US20090269358 Proteins with Improved Solubility and Methods for Producing and Using Same
10/29/2009	US20090269349 Antigenic polypeptides
10/29/2009	US20090269333 Replikin peptides in rapid replication of glioma cells and in influenza epidemics

1 ... 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 ... 1798